Objective: The objective is to assess the quality of life of patients with Parkinson’s disease followed in Senegal.

Background: Parkinson’s disease is a neurodegenerative disease, the incidence of which is generally between 10 and 50/100 000 people per year and the prevalence between 100 and 300/100 000 people. In sub-Saharan Africa, the problem remains unsolved because of the therapeutic gap linked to the inaccessibility of the latest generation of drug treatments and surgical treatments.

Method: This is a descriptive and  prospective study on the quality of life of patients with Parkinson’s disease and monitored from January 2, 2017 to December 31, 2018. The data were collected at using internationally validated questionnaires and scales. The MDS-UPRS III scores, Schwab and England’s daily activity scale, PDQ39, MoCA, apathy inventory and Beck’s depression inventory were used.

Results: Twenty-three cases were collected with a male predominance (sex ratio 1.8). The average age was 63 years with extremes ranging from 46 to 81 years. Seven patients were under 55 years of age. On the professional level, three of the 10 patients active at the time of the diagnosis had to stop their work and 4 had to change their work station. Clinically, the akineto-rigid form was predominantly 95.6%. Seven patients reported dysarthria and 10 patients wrote disorders. The MDS-UPDRS score varied between 21 and 87. According to the daily activity scale of SCHAWB and ENGLAND 34.8% of patients had a score of 100%, 17.4% of patients had a score of 80 to 90% , 30.4% of patients had a score between 40 and 60%, 17.4% of patients had a score between 20 and 40%. PDQ39 ranged from 9 to 37 in all patients with an average of 28. The average MoCA score was 21. Apathy was found in 65% of patients and depression in 39% of patients. Therapeutically all our patients were on L-dopa and / or first generation dopaminergic agonist associated with the management of comorbidities. The outcome was favorable in 52% with improvement in motor and non-motor signs, stationary in 39% of patients with persistent motor signs and listlessness, and unfavorable in 9% of patients with motor worsening, listlessness and depression.

Conclusion: The quality of life of Parkinson’s patients largely depends on non-motor signs that need to be diagnosed early and well managed, especially in resource-constrained countries where access to treatment remains a major problem.

References: 1. Von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005; 15(4): 473-490. 2. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014; 29(13): 1583-1590. 3. Reichmann H, Schneider C, Lohle M. Non motor features of Parkinson’s disease:Depression and dementia. Parkinsonism Relat Disord. Dec 2009; 15 Suppl 3: S87-92. 4. Haudhuri KR, Odin P. The challenge of non-motor symptoms in Parkinson’s disease. Prog Brain Res. 2010; 184: 325-341. 5. Chaudhuri K R, Martinez-Martin P, Schapira A H et al. International multicenter pilot study of the first comprehensive self completed no motor symptoms questionnaire for Parkinson’s disease. Movement Disorders 2006; 21: 916-923 6. Daniel D. Truong A, Roongroj B, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. Journal of the Neurological Sciences 2008; 266: 216-228.

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/quality-of-life-study-of-patients-living-with-parkinsons-disesae-in-sub-saharan-africa/